EUVIMEDEUVIMED entdecken
Crossref

Polysaccharides of Cistanche tubulosa (Schenk) R. Wight alleviate ulcerative colitis by modulating short-chain fatty acid production and the MAPK/NF-κB pathway through regulation of the gut microbiota

Shuyi Ji, Dongxuan Zheng, Yu Wang, Yawen Bai, Junjie Tan, XueMei Qin, Jun Yao, Jing Shen

International Immunopharmacology · 2026-01 · 169 · 116015

DOI: 10.1016/j.intimp.2025.116015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026-01. Verfasst von Shuyi Ji und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Xinjiang Medical University, Urumqi, China. Electronic address: jishuyi@stu.xjmu.edu.cn. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Colitis, Ulcerative, Cistanche, Fatty Acids, Volatile. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 90 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Technology Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ulcerative colitis (UC) is a form of inflammatory bowel disease and a serious and increasingly prevalent global health concern. Cistanche tubulosa (Schenk) R. Wight is a traditional Chinese medicine containing polysaccharides and used to regulate immunity and replenish essence to alleviate UC. However, the mechanism of action of C. tubulosa polysaccharides (CTCA) for the treatment of UC needs further validation. OBJECTIVE: The study aimed to investigate the protective effect of CTCA in mice with chronic UC and to explore its underlying mechanisms through short-chain fatty acid (SCFA) analysis and 16S rRNA sequencing. METHODS: In vitro experiments using RAW264.7 cells and in vivo studies using a C57BL/6 chronic UC mouse model were conducted to examine the potential role of CTCA in alleviating inflammation. 16S rRNA sequencing was used to evaluate the effect of CTCA on the gut microbiota, and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis was performed to predict potential pathways involved in its therapeutic effects. SCFA analysis, quantitative PCR (qPCR), and Western blotting (WB) were used to validate the pathway predictions from KEGG analysis. Pseudo-germfree mice experiments were used to validate the impact of the gut microbiota on the therapeutic effects of CTCA in UC. RESULTS: In vitro and in vivo experiments have demonstrated the potential of CTCA in treating chronic UC induced by dextran sulfate sodium (DSS). 16S rRNA sequencing results demonstrated that CTCA can restore intestinal microbial homeostasis in UC mice. KEGG analysis revealed that carbohydrate metabolism and immune regulation are involved in the therapeutic efficacy of CTCA. qPCR and WB experiments verified that CTCA act through modulation of the mitogen-activated protein kinase (MAPK)/nuclear factor kappa B (NF-κB) signalling pathway. The combined analyses suggested a strong correlation between gut microbiota and CTCA for the treatment of UC. Pseudo-germfree mice experiments validated that the anti-inflammatory and gut-protective functions of CTCA in UC were limited in the absence of the gut microbiota. CONCLUSIONS: CTCA protects the intestinal mucosal barrier and alleviates inflammation, thereby ameliorating DSS-induced chronic ulcerative colitis in mice. This effect is strongly correlated with CTCA's regulation of SCFA metabolism mediated by the gut microbiota and the MAPK/NF-κB pathway. CTCA holds potential application as a dietary supplement to modulate gut microecology as a clinical option for the treatment of UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeColitis, UlcerativeCistancheFatty Acids, VolatilePolysaccharidesAnti-Inflammatory AgentsAnimalsMiceMice, Inbred C57BLRAW 264.7 CellsNF-kappa BDisease Models, AnimalMaleDextran SulfateMAP Kinase Signaling SystemRNA, Ribosomal, 16SSignal Transduction

Stichwörter der Autor:innen

Cistanche tubulosa (Schenk) R. WightGut microbiotaMAPK/NF-κB pathwayPolysaccharideUlcerative colitis

Substanzen

Fatty Acids, VolatilePolysaccharidesNF-kappa BDextran SulfateAnti-Inflammatory AgentsRNA, Ribosomal, 16S

Autor:innen und Institutionen

  • School of Pharmacy, Xinjiang Medical University, Urumqi, China. Electronic address: jishuyi@stu.xjmu.edu.cn.
  • School of Pharmacy, Xinjiang Medical University, Urumqi, China. Electronic address: zdx15651074992@163.com.
  • School of Pharmacy, Xinjiang Medical University, Urumqi, China. Electronic address: rubyw2022@163.com.
  • School of Pharmacy, Xinjiang Medical University, Urumqi, China. Electronic address: baiyawen@stu.xjmu.edu.cn.
  • School of Pharmacy, Xinjiang Medical University, Urumqi, China. Electronic address: tanjunjie@stu.xjmu.edu.cn.
  • Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, China. Electronic address: qinxm@sxu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Technology Development

Zitieren

APA

Ji, S., Zheng, D., Wang, Y., Bai, Y., Tan, J., Qin, X., Yao, J., & Shen, J. (2026). Polysaccharides of Cistanche tubulosa (Schenk) R. Wight alleviate ulcerative colitis by modulating short-chain fatty acid production and the MAPK/NF-κB pathway through regulation of the gut microbiota. International Immunopharmacology, 169, 116015. https://doi.org/10.1016/j.intimp.2025.116015

Vancouver

Ji S, Zheng D, Wang Y, Bai Y, Tan J, Qin X, et al. Polysaccharides of Cistanche tubulosa (Schenk) R. Wight alleviate ulcerative colitis by modulating short-chain fatty acid production and the MAPK/NF-κB pathway through regulation of the gut microbiota. International Immunopharmacology. 2026;169:116015. doi:10.1016/j.intimp.2025.116015

BibTeX
@article{Ji2026,
  author = {Ji, Shuyi and Zheng, Dongxuan and Wang, Yu and Bai, Yawen and Tan, Junjie and Qin, XueMei and Yao, Jun and Shen, Jing},
  title = {Polysaccharides of Cistanche tubulosa (Schenk) R. Wight alleviate ulcerative colitis by modulating short-chain fatty acid production and the MAPK/NF-κB pathway through regulation of the gut microbiota},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {169},
  pages = {116015},
  doi = {10.1016/j.intimp.2025.116015}
}
Kostenlos starten →